In a Wnt-responsive L-cell reporter assay, endo-IWR-1 had a reported EC50 of 0.2 μM. Exo-IWR was 25-fold less active (EC50 5 μM), showing that the two forms should not be treated as interchangeable. [2]
At 5 μM, IWR-1-endo attenuated Wnt3a-stimulated migration of MDA-MB-231 cells over 14 h, while basal motility was not reduced. This result is conditional on Wnt stimulation and the tested culture conditions. [1]
Endo/exo comparison in a Wnt reporter assay
Cell-based study · Mouse L-cells expressing Wnt3A and control and Wnt-responsive reporters [2]
Endo-IWR-1 suppressed Wnt reporter activity more potently than exo-IWR. The paper labels these values EC50, rather than an enzyme IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series; no treatment concentration substituted for EC50
- Method
- Cell-based luciferase reporter assay
- Reported limits
- Assay duration, vehicle and replicate number are not specified in the selected paper’s assay footnote or figure captions.
Methods and source locations
Compound reported in the paper: IWR-1-endo; Compound label in the paper: endo-IWR 1 (compound 1)
Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.
Figures 1–2; norbornyl SAR paragraph; footnote 6
Inhibition of Wnt/β-catenin reporter response: Reporter assay; value printed in Figure 1 — Figure 1 (compound 1); footnote 6
Exo-IWR comparator and stereochemical sensitivity: Figure 2 printed value and accompanying SAR text; comparator is not the product — Figure 2; norbornyl SAR paragraph
Axin1 accumulation in breast cancer cells
Cell-based study · Human MDA-MB-231 breast cancer cells [1]
IWR-1-endo increased Axin1 and tankyrase 1/2 protein abundance relative to DMSO, with or without Wnt3a. This cellular experiment does not measure enzyme affinity or establish direct binding.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- Overnight compound treatment; Wnt3a-conditioned medium for 4 h
- Method
- Immunoblot of total cell lysates; actin loading control
- Vehicle
- DMSO
- Co-treatment
- Parallel control-conditioned and Wnt3a-conditioned medium conditions; XAV939 is a separate comparator.
- Reported limits
- Exact overnight hours and replicate number for Figure 1D are not stated in its caption.
Methods and source locations
Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1-endo
Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.
Figure 1D and caption; Results first subsection; Materials and Methods: Compounds, Immunoblotting
Axin1 and TNKS1/TNKS2 abundance: Anti-Axin1 and anti-tankyrase immunoblot; actin loading control — Figure 1D; corresponding Results paragraph
Wnt-stimulated versus basal migration
Cell-based study · Confluent human MDA-MB-231 monolayers [1]
IWR-1 attenuated Wnt3a-induced wound closure at 14 h but did not reduce basal motility in the absence of Wnt3a.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 14 h
- Method
- Wound-healing assay; cell-free area quantified with ImageJ relative to time 0
- Vehicle
- DMSO
- Co-treatment
- Control or Wnt3a-conditioned medium with 2.5% FBS; XAV939 tested separately.
- Reported limits
- Replicate number and error-bar definition for Figure 4 are not given in its caption; no numerical percentage is extracted.
Methods and source locations
Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1 (paper reagent: IWR-1-endo)
Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.
Figure 4A–B and caption; Results: XAV939 inhibits Wnt3A-induced cell migration in MDA-MB-231 breast cancer cells; Materials and Methods: Wound healing and cell migration assay
Wnt3a-stimulated and basal wound closure: Matched DMSO, control-medium and Wnt3a-medium comparisons at 14 h; images and graph viewed — Figure 4A–B; corresponding Results paragraph